Diabetic retinopathy screening, licensed to local partners.
Deployed under local partners’ regulatory frameworks (India, Thailand, Australia) rather than a device Google itself markets as CE/FDA cleared in those markets.
Not the primary source used here.
Third-party industry report (‘AI Weekly’) citing over one million patients screened.
Reported to have passed one million patients screened, via partners in India and Thailand — deployment outside the US/Europe, relevant to global-equity framing.
Regulatory responsibility sits with local licensees, not Google directly — state this precisely.
This profile is not medical advice or an endorsement. Hospitals should perform their own due diligence (regulatory compliance, GDPR, cybersecurity, integration, local clinical validation). How we evaluate
Every profile documents the precise indication, regulatory status, vendor-supported and independent evidence, real-world deployment, limits and dated sources.
A independent systematic review or prospective multicentre study · B at least one independent peer-reviewed study · C peer-reviewed, vendor-supported · D vendor claims only.
Vendors, authors and clinicians can request a correction. Corrections are dated on the profile.